title: What has happened to gene therapy?
abstract: Trials have demonstrated the feasibility of gene therapy in correcting the gene defect in monogenic disorders such as severe combined immune deficiency and cystic fibrosis, but there are still obstacles and ethical issues to overcome.
  
  
  CONCLUSIONS
  With appropriate research, better delivery strategies and adherence to good standard clinical research and practice, gene therapy research will lead to clinical implementation in monogenic and multifactorial disorders including cancer, neurodegenerative disorders and vascular disease.
authors.affiliation: Department of Medical Genetics, Belfast City Hospital, Northern Ireland, UK. nc.nevin@bch.n-i.nhs.uk
authors.forename: N C
authors.initials: NC
authors.lastname: Nevin
mesh_terms: D003550:Cystic Fibrosis / Q000628:therapy; D004992:Ethics, Medical; D005240:Feasibility Studies; D005544:Forecasting; D015316:Genetic Therapy / Q000331:legislation & jurisprudence / Q000639:trends; D006801:Humans; D016511:Severe Combined Immunodeficiency / Q000628:therapy; D006113:United Kingdom